In­sulin prices in the Sen­ate hot seat: PBM and phar­ma fin­ger-point­ing con­tin­ues as land­scape shifts

The CEOs from Eli Lil­ly, Sanofi and No­vo Nordisk and ex­ec­u­tives from top phar­ma­cy ben­e­fit man­agers were in the hot seat on Capi­tol Hill on Wednes­day, with sen­a­tors on both sides of the aisle rail­ing against the com­pa­nies for keep­ing in­sulin list prices high and in­creas­ing out-of-pock­et costs.

“The bot­tom line of this hear­ing is not com­pli­cat­ed,” Sen­ate HELP Com­mit­tee Chair Bernie Sanders (I-VT) said in his open­ing re­marks. “Peo­ple are say­ing, ‘enough is enough.’ They are sick and tired of pay­ing out­ra­geous­ly high prices … Too many Amer­i­cans have died for ra­tioning their in­sulin.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER